Evaluation of the effect of NAC in colistin-induced nephrotoxicity

Phase 2

Recruiting

• Conditions: nephrotoxicity.; Nephropathy induced by other drugs, medicaments and biological substances; N14.1

• Registration Number: IRCT20200328046886N5
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 48

Inclusion Criteria

Patients over 18 years old
Use of colistin for five days or longer as IV antimicrobial therapy in patients with nosocomial infections
Obtaining a written informed consent form from all patients or their guardians

Exclusion Criteria

Receive NAC less than 24 hours before the first dose of colistin
Patients undergoing hemodialysis or peritoneal dialysis
Receiving contrast material for radiological imaging
Pregnant and lactating women
Known allergy to colistin or N-acetylcysteine (NAC)
Patient with recent history of cardiopulmonary resuscitation
Patients with systolic blood pressure <90 mmHg
GFR<60 ml/min

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rinary N-acetyl-beta-D glucosaminidase (NAG) level. Timepoint: First and fifth day of study. Method of measurement: Through the N-acetyl-beta-D glucosaminidase (NAG) urinary measurement kit.;Severity of kidney damage. Timepoint: Daily during the intervention period. Method of measurement: RIFLE classification system.